Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

A model of the three-dimensional structure of human interferon responsive factor 1 and its modifications upon phosphorylation or phosphorylation-mimicking mutations.

Storchi L, Remoli AL, Marsili G, Acchioni C, Acchioni M, Battistini A, Sgarbanti M, Marrone A.

J Biomol Struct Dyn. 2018 Dec 20:1-12. doi: 10.1080/07391102.2018.1557558. [Epub ahead of print]

PMID:
30569833
2.

Development and Validation of a Novel Dual Luciferase Reporter Gene Assay to Quantify Ebola Virus VP24 Inhibition of IFN Signaling.

Fanunza E, Frau A, Sgarbanti M, Orsatti R, Corona A, Tramontano E.

Viruses. 2018 Feb 24;10(2). pii: E98. doi: 10.3390/v10020098.

3.

HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation.

Remoli AL, Marsili G, Perrotti E, Acchioni C, Sgarbanti M, Borsetti A, Hiscott J, Battistini A.

MBio. 2016 Oct 18;7(5). pii: e01528-16. doi: 10.1128/mBio.01528-16.

4.

IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better.

Marsili G, Perrotti E, Remoli AL, Acchioni C, Sgarbanti M, Battistini A.

J Interferon Cytokine Res. 2016 Jul;36(7):414-32. doi: 10.1089/jir.2016.0002. Review.

PMID:
27379864
5.

Type I IFN--a blunt spear in fighting HIV-1 infection.

Acchioni C, Marsili G, Perrotti E, Remoli AL, Sgarbanti M, Battistini A.

Cytokine Growth Factor Rev. 2015 Apr;26(2):143-58. doi: 10.1016/j.cytogfr.2014.10.004. Epub 2014 Oct 30. Review.

PMID:
25466629
6.

HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.

Battistini A, Sgarbanti M.

Viruses. 2014 Apr 14;6(4):1715-58. doi: 10.3390/v6041715. Review.

7.

IκB kinase ε targets interferon regulatory factor 1 in activated T lymphocytes.

Sgarbanti M, Marsili G, Remoli AL, Stellacci E, Mai A, Rotili D, Perrotti E, Acchioni C, Orsatti R, Iraci N, Ferrari M, Borsetti A, Hiscott J, Battistini A.

Mol Cell Biol. 2014 Mar;34(6):1054-65. doi: 10.1128/MCB.01161-13. Epub 2014 Jan 6.

8.

Therapeutics for HIV-1 reactivation from latency.

Sgarbanti M, Battistini A.

Curr Opin Virol. 2013 Aug;3(4):394-401. doi: 10.1016/j.coviro.2013.06.001. Epub 2013 Jun 28. Review.

PMID:
23810462
9.

The development of immune-modulating compounds to disrupt HIV latency.

Remoli AL, Marsili G, Battistini A, Sgarbanti M.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):159-72. doi: 10.1016/j.cytogfr.2012.05.003. Epub 2012 Jul 4. Review.

PMID:
22766356
10.

HIV-1, interferon and the interferon regulatory factor system: an interplay between induction, antiviral responses and viral evasion.

Marsili G, Remoli AL, Sgarbanti M, Perrotti E, Fragale A, Battistini A.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):255-70. doi: 10.1016/j.cytogfr.2012.06.001. Epub 2012 Jun 27. Review.

PMID:
22748237
11.

The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus.

ElHefnawi M, Hassan N, Kamar M, Siam R, Remoli AL, El-Azab I, AlAidy O, Marsili G, Sgarbanti M.

Bioinformatics. 2011 Dec 15;27(24):3364-70. doi: 10.1093/bioinformatics/btr555. Epub 2011 Oct 11.

PMID:
21994230
12.

Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes.

Muto V, Stellacci E, Lamberti AG, Perrotti E, Carrabba A, Matera G, Sgarbanti M, Battistini A, Liberto MC, Focà A.

J Virol. 2011 May;85(10):5070-80. doi: 10.1128/JVI.02114-10. Epub 2011 Mar 9.

13.

Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination.

Castaldello A, Sgarbanti M, Marsili G, Brocca-Cofano E, Remoli AL, Caputo A, Battistini A.

J Cell Physiol. 2010 Sep;224(3):702-9. doi: 10.1002/jcp.22169.

PMID:
20432465
14.

Generation of a human immunodeficiency virus type 1 chronically infected monkey B cell line expressing low levels of endogenous TRIM5alpha.

Ridolfi B, Catone S, Sgarbanti M, Sernicola L, Battistini A, Parolin C, Titti F, Borsetti A.

J Cell Physiol. 2009 Dec;221(3):760-5. doi: 10.1002/jcp.21914.

PMID:
19746418
15.

IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer.

Sgarbanti M, Remoli AL, Marsili G, Ridolfi B, Borsetti A, Perrotti E, Orsatti R, Ilari R, Sernicola L, Stellacci E, Ensoli B, Battistini A.

J Virol. 2008 Apr;82(7):3632-41. doi: 10.1128/JVI.00599-07. Epub 2008 Jan 23.

16.

IRF-7: new role in the regulation of genes involved in adaptive immunity.

Sgarbanti M, Marsili G, Remoli AL, Orsatti R, Battistini A.

Ann N Y Acad Sci. 2007 Jan;1095:325-33.

PMID:
17404045
17.

Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription.

Marsili G, Remoli AL, Sgarbanti M, Battistini A.

Ann N Y Acad Sci. 2004 Dec;1030:636-43.

PMID:
15659847
18.

Analysis of the signal transduction pathway leading to human immunodeficiency virus-1-induced interferon regulatory factor-1 upregulation.

Sgarbanti M, Marsili G, Remoli AL, Ridolfi B, Stellacci E, Borsetti A, Ensoli B, Battistini A.

Ann N Y Acad Sci. 2004 Dec;1030:187-95.

PMID:
15659797
19.

A requirement for NF-kappaB induction in the production of replication-competent HHV-8 virions.

Sgarbanti M, Arguello M, tenOever BR, Battistini A, Lin R, Hiscott J.

Oncogene. 2004 Jul 29;23(34):5770-80.

PMID:
15235582
20.

On the role of interferon regulatory factors in HIV-1 replication.

Marsili G, Borsetti A, Sgarbanti M, Remoli AL, Ridolfi B, Stellacci E, Ensoli B, Battistini A.

Ann N Y Acad Sci. 2003 Dec;1010:29-42. Review.

PMID:
15033691

Supplemental Content

Loading ...
Support Center